King of Prussia, PA, United States of America

Robert B Kirkpatrick

USPTO Granted Patents = 9 (Patent Applications = 1)

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.5

ph-index = 5

Forward Citations = 73(Granted Patents)

Company Filing History:

7 out of 2,198

Smithkline Beecham Corporation

patents

1 out of 4

Smithkline Beechum P.l.c.

Years Active: 1998-2010

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7736639 - Method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof (2010-06-15),

2. 7442526 - Method for preparing a physiologically active IL-18 polypeptide (2008-10-28),

3. 7311902 - Conjugates comprising human IL-18 and substitution mutants thereof (2007-12-25),

4. 7186528 - Method for preparing a physiologically active IL-18 polypeptide (2007-03-06),

5. 7067280 - Human cartilage glycoprotein (2006-06-27),

6. 6576427 - Human cartilage glycoprotein (2003-06-10),

7. 5811535 - Human cartilege gp39-like gene (1998-09-22),

8. 5773259 - Tissue remodeling proteins (1998-06-30),

9. 5726061 - Method of diagnosing and monitoring colorectal cancer (1998-03-10),

Title: The Innovative Contributions of Robert B. Kirkpatrick

Introduction

Robert B. Kirkpatrick is a notable inventor based in King of Prussia, Pennsylvania. He has made significant contributions to the field of medical science, particularly in cancer treatment. With a total of nine patents to his name, Kirkpatrick's work has the potential to impact the lives of many patients.

Latest Patents

Among his latest patents is a method of treating cancer by administering conjugates comprising human IL-18 and substitution mutants thereof. This invention focuses on methods of treating cancer in patients in need thereof with human interleukin-18 (IL-18) polypeptides that are conjugated to water-soluble polymers at specific sites on the human IL-18 protein. Another significant patent is for a method for preparing a physiologically active IL-18 polypeptide. This invention provides a method for producing physiologically active human Interleukin-18 (IL-18), which is crucial for therapeutic applications.

Career Highlights

Kirkpatrick has worked with prominent companies such as SmithKline Beecham Corporation and SmithKline Beecham P.L.C. His experience in these organizations has contributed to his expertise in the field of biotechnology and pharmaceuticals.

Collaborations

Throughout his career, Kirkpatrick has collaborated with notable individuals, including Kyung Oh Johanson and Martin M. Rosenberg. These collaborations have likely enriched his research and development efforts.

Conclusion

Robert B. Kirkpatrick's innovative work in cancer treatment and his extensive patent portfolio highlight his significant contributions to medical science. His inventions have the potential to advance therapeutic methods and improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.